Aurobindo Pharma, a mid-size pharmaceutical company, today received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Telmisartan tablets USP 20mg, 40 mg, and 80mg.

According to IMS, Telmisartan Tablets are indicated in the treatment of essential hypertension and has an estimated market size of USD 92 million for the twelve months ending July 2015.

Shares of the company declined Rs 12.6, or 1.71%, to settle at Rs 722.80. The total volume of shares traded was 201,549 at the BSE (Friday).

Total volume of shares traded on the bourses today was lower by 25.62% to 1,764,646 compared with 22-day average volume of 2,372,334.